Data: Toxicity, therapeutics studied

The study, published in the November issue of Advances in Therapy, compared the in vitro effects on both cultured human corneal and conjunctival epithelial cells of five prostaglandin analogue formulations. The test solutions included 0.0015% tafluprost with 0.010% BAK (Taflotan, Santen Pharmaceutical), 0.004% travoprost with 0.015% BAK (Travatan, Alcon), 0.004% travoprost with 0.001% PQ (Travatan PQ, Alcon), 0.004% travoprost with the oxidizing preservative sofZia (Travatan Z, Alcon), and 0.005% latanoprost with 0.020% BAK (Xalatan, Pfizer). Balanced salt solution (BSS) was used as the live control.

Dr. Kahook and colleagues found that exposure to an increasing percentage of BAK caused a dose-dependent increase in both conjunctival and corneal epithelial cell death compared with BSS control.

The study also found that the toxicity of the prostaglandin analogues preserved with BAK was close to that of their respective BAK concentrations alone. Also, confirming previously reported findings, the study determined that travoprost with 0.015% BAK performed better than 0.015% BAK alone, indicating a possible cytoprotective effect of the prostaglandin analogue.

In the study, confluent cultures of human corneal and conjunctival cells were assayed with 100 μl of the different glaucoma medications for 25 minutes at 37° C and 5% CO₂. SofZia and a range of concentrations of BAK (0.001% to 0.050%) were also tested.

According to Dr. Kahook, a tremendous amount of information about the tolerability of different formulations of glaucoma drugs has been reported, but the lack of appropriate metrics has limited the clinical relevance of the obtained data.

"We don't have any great, reproducible metrics for ocular surface disease that can be done in a multi-site study. Because of the lack of metrics, there has been difficulty in correlating in vitro and in vivo findings," he explained.

Data from in vivo studies are available on specific patient populations, such as those who have had previous problems with formulations containing BAK or patients who have severe ocular surface disease. These studies have shown that changing from a drop preserved with BAK to one that is not results in improvement in metrics such as tear break-up time or lissamine green staining.^1,2

However, it would be difficult to expand these findings to all patient populations because current metrics are insufficient to identify the subtle changes that can occur in the ocular surface when switching medications, Dr. Kahook said. He added that many laboratories are investigating better ways to understand how in vitro findings compare with in vivo responses and developing better clinical diagnostic methodologies for making direct comparisons, if any exist.

References

1. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-295.

2. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329-336.

fyiMalik Y. Kahook, MD
Phone: 720/848-2500
E-mail: malik.kahook@ucdenver.edu

Dr. Kahook has received research support from Actelion, Alcon, Allergan, the American Glaucoma Society, Genentech, Merck, and the State of Colorado.